Grey Wolf

News

Immuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase tumour visibility.

News

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.